Portfolio Asset N°1

CYTEA BIO

A pre-clinical stage biotech company developing therapeutic products by combining genetically unmodified effector cells and engineered targeting ligands. The patented Pin™ Platform enables practically limitless combinations of effector mechanisms and targeting ligands for applications in oncology and immunology.

Visit cytea.bio